ESAB Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ESAB Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.84B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.74B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $2.77B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $2.59B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.43B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.95B | Mar 7, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.84B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.74B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $2.77B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $2.59B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.43B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.95B | Mar 7, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.05B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.04B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.02B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $885.53M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $837.98M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $682.47M | Mar 7, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.77M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $264.84M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $205.29M | Feb 20, 2025 |
| FY2022 | Dec 31, 2022 | $223.75M | Mar 7, 2023 |
| FY2022 | Dec 31, 2021 | $235.11M | Mar 7, 2023 |
| FY2022 | Dec 31, 2020 | $157.41M | Mar 7, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $412.17M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $447.45M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $404.17M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $329.07M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $306.21M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $202.13M | Mar 7, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.00M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $39.20M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $38.80M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $36.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $39.70M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $34.80M | Mar 7, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $608.42M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $579.78M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $587.48M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $533.37M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $512.82M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $458.71M | Mar 7, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $260.57M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $355.40M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $330.49M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $214.36M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $250.74M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $309.18M | Mar 7, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.29M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $51.78M | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $48.18M | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $40.24M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $35.58M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $40.14M | Mar 7, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.77B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $4.03B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $3.83B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.75B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.46B | Mar 7, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.55B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.23B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $2.18B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.37B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $959.53M | Mar 7, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.17B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.77B | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $1.61B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.35B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.46B | Mar 7, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.95B | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.65B | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | $1.59B | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | $1.53B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.53B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.55B | Mar 7, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $800.81M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $597.18M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $350.56M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $159.23M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 7, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.86M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | $249.36M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | $102.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $72.02M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $41.21M | Mar 7, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.02B | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | $1.22B | Feb 29, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Mar 7, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 20, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 20, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Mar 7, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 60.72M | Feb 20, 2026 |
| FY2025 | Dec 31, 2024 | 60.52M | Feb 20, 2026 |
| FY2024 | Dec 31, 2023 | 60.30M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 60.09M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 100 | Mar 7, 2023 |